Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Remission of Graves’ Disease During Anti-Thyroid Drug Therapy: Time to Reconsider the Mechanism?
source: European Journal of Endocrinology / European Federation of Endocrine Societies
year: 2006
authors: Laurberg P
summary/abstract:Therapy of Graves’ hyperthyroidism with thionamide anti-thyroid drugs is accompanied by a gradual remission of the autoimmune aberration in the majority of patients. The most likely mechanism behind this remission has been considered to be a direct immunosuppressive effect of thionamide drugs. However, a number of findings in clinical studies of patients with Graves’ disease indicate that remission is probably not caused by a special effect of thionamide drugs.
Many studies have shown that remission is linked to restoration of the euthyroid state, and that it is independent of drug dose and type. Moreover, similar remission is observed when patients become euthyroid after thyroid surgery. In an explanatory model described, it is assumed that the autoimmune aberration of Graves’ disease is often basically quit mild and self-limiting. Patients may become ill by the running of a vicious cycle of hyperthyroidism worsening the autoimmunity, and autoimmunity worsening the hyperthyroidism.
Once patients are made euthyroid by one or the other drug or by thyroid surgery, the majority of patients will gradually enter remission of the disease. The conclusion that remission is associated with restoration of the euthyroid state, and that it is not a special drug effect, highlights the importance of making and keeping patients with Graves’ disease euthyroid.
organization: Aarhus University Hospital, DenmarkDOI: 10.1530/eje.1.02295
read more full text
myBinderRelated Content
-
Graves’ Disease After Treatment With Alemtuzumab for Multiple SclerosisContext: Alemtuzumab, a humanized monoc...
-
A Validated Tool Can Predict Risk of Developing Thyroid Eye Disease During Antithyroid Drug Treatment of Graves’ D...Over-activity of the thyroid gland, call...
-
Double-Blind, Placebo-Controlled, Randomized Trial of Selenium in Graves HyperthyroidismContext: Supplemental selenium (Se) may...
-
Which Factors Predict the Outcome of Radioactive Iodine Therapy of Graves’ Disease?Graves’ disease is the most common cau...
-
The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves’ Ophthalmopathy PatientsPurpose: The purpose of this study is t...
-
The Effect of Short-Term Treatment With Lithium Carbonate on the Outcome of Radioiodine Therapy in Patients With Lon...Objective: The outcome of radioiodine t...
-
New Therapeutic Horizons for Graves’ HyperthyroidismGraves’ hyperthyroidism is characteriz...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google